Profile data is unavailable for this security.
About the company
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
- Revenue in USD (TTM)0.00
- Net income in USD-960.98m
- Incorporated2014
- Employees809.00
- LocationRevolution Medicines Inc700 Saginaw DrREDWOOD CITY 94063United StatesUSA
- Phone+1 (650) 481-6801
- Fax+1 (302) 636-5454
- Websitehttps://www.revmed.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIO-TECHNE Corp | 1.22bn | 79.96m | 9.38bn | 3.10k | 118.08 | 4.65 | 51.03 | 7.71 | 0.5076 | 0.5076 | 7.74 | 12.90 | 0.4682 | 2.06 | 6.04 | 392,121.60 | 3.08 | 7.62 | 3.27 | 8.13 | 66.60 | 67.49 | 6.58 | 16.74 | 3.08 | 56.92 | 0.1145 | 26.72 | 5.23 | 10.55 | -56.35 | -20.37 | -9.74 | -4.36 |
| Madrigal Pharmaceuticals Inc | 740.64m | -289.13m | 10.55bn | 528.00 | -- | 16.86 | -- | 14.25 | -13.01 | -13.01 | 33.39 | 27.56 | 0.6082 | 0.9008 | 10.30 | 1,402,727.00 | -23.74 | -68.48 | -30.98 | -85.32 | 95.25 | -- | -39.04 | -876.55 | 3.26 | -- | 0.3519 | -- | -- | -- | -24.69 | -- | 106.52 | -- |
| Summit Therapeutics Inc | 0.00 | -921.62m | 11.14bn | 159.00 | -- | 57.93 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2583 | 0.00 | -- | -- | 0.00 | -241.08 | -78.31 | -287.72 | -86.84 | -- | -- | -- | -31,307.77 | -- | -- | 0.00 | -- | -- | -- | 64.01 | -- | -16.43 | -- |
| Exelixis Inc | 2.32bn | 782.57m | 11.41bn | 1.08k | 15.78 | 5.33 | 14.05 | 4.92 | 2.78 | 2.78 | 8.23 | 8.23 | 0.8011 | 3.80 | 8.40 | 2,154,249.00 | 27.02 | 13.68 | 31.41 | 15.65 | 96.39 | 96.33 | 33.73 | 20.55 | 3.50 | -- | 0.00 | 0.00 | 6.98 | 18.63 | 50.13 | 47.58 | -22.60 | -- |
| Medpace Holdings Inc | 2.53bn | 451.12m | 12.15bn | 5.90k | 27.99 | 26.39 | 25.35 | 4.80 | 15.29 | 15.29 | 85.67 | 16.22 | 1.24 | -- | 7.24 | 428,853.20 | 22.13 | 18.52 | 55.42 | 37.53 | 30.06 | 29.60 | 17.83 | 17.15 | -- | -- | 0.00 | 0.00 | 19.97 | 22.27 | 11.57 | 25.50 | 0.0102 | -- |
| Ionis Pharmaceuticals Inc | 966.96m | -256.34m | 13.06bn | 1.07k | -- | 21.02 | -- | 13.50 | -1.71 | -1.71 | 5.87 | 3.84 | 0.3163 | 0.6054 | 45.47 | 904,542.60 | -8.39 | -11.71 | -10.45 | -13.72 | 98.78 | 98.42 | -26.51 | -44.15 | 2.78 | -- | 0.7414 | -- | -10.48 | -8.88 | -23.92 | -- | 7.94 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -3.58m | 15.44bn | 12.00 | -- | 3,176.36 | -- | -- | -0.0073 | -0.0073 | 0.00 | 0.0098 | 0.00 | -- | -- | 0.00 | -50.50 | -53.93 | -53.75 | -65.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.68 | -- | 5.32 | -- |
| Revolution Medicines Inc | 0.00 | -960.98m | 18.62bn | 809.00 | -- | 11.44 | -- | -- | -5.18 | -5.18 | 0.00 | 8.42 | 0.00 | -- | -- | 0.00 | -47.87 | -28.38 | -52.53 | -30.68 | -- | -- | -- | -1,324.37 | -- | -- | 0.1384 | -- | -100.00 | -- | -37.52 | -- | 31.83 | -- |
| Exact Sciences Corp | 3.08bn | -986.58m | 19.70bn | 6.90k | -- | 7.82 | -- | 6.39 | -5.32 | -5.32 | 16.43 | 13.20 | 0.4873 | 6.67 | 10.80 | 446,671.40 | -15.60 | -11.29 | -17.40 | -12.38 | 67.37 | 71.21 | -32.01 | -30.90 | 2.44 | -- | 0.4833 | -- | 10.37 | 25.78 | -403.97 | -- | 0.9474 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 15.37m | 7.95% |
| Farallon Capital Management LLCas of 31 Dec 2025 | 14.58m | 7.54% |
| Janus Henderson Investors US LLCas of 30 Sep 2025 | 11.20m | 5.79% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 9.46m | 4.89% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 9.40m | 4.86% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 7.92m | 4.10% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 6.99m | 3.62% |
| Paradigm BioCapital Advisors LPas of 30 Sep 2025 | 6.22m | 3.22% |
| Bellevue Asset Management AGas of 30 Sep 2025 | 5.57m | 2.88% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2025 | 4.78m | 2.47% |
